Posts

Posted on

OCEANIA CRUISES SET TO TAKE GUESTS TO THE STARS AND BACK WITH FIVE EXCEPTIONAL 2026 SOLAR ECLIPSE SAILINGS

PR Newswire

Five Luxury Voyages Positioned in Prime Eclipse-Viewing Locations Promise an Unparalleled Celestial Experience at Sea


MIAMI
, April 16, 2025 /PRNewswire/ — Oceania Cruises®, the world’s leading culinary- and destination-focused cruise line, today announced four additional 2026 solar eclipse sailings, providing guests with five exceptional itineraries to view the cosmic event – the most for any cruise line globally.

The collection of once-in-a-lifetime voyages will see guests perfectly positioned to experience the phenomenon on August 12, 2026, off the shores of Ireland, Iceland, Portugal, and the United Kingdom.

Each of the itineraries will navigate prime locations within the eclipse’s path, maximizing viewing conditions at sea. With Oceania Marina™ positioned in the path of 100 percent totality and Oceania Insignia™, Oceania Sirena™, and two voyages aboard Oceania Vista® each in the path of more than 90 percent totality, these sailings promise an unforgettable experience for travelers and astronomy enthusiasts alike.

Oceania Cruises’ hallmark enrichment programs will enhance the solar eclipse with expert insights from an impressive roster of guest speakers, including esteemed astronomers and NASA ambassadors. Travelers can delve deep into the scientific and cultural significance of solar eclipses, further enhancing their voyage.

“There is no better way to witness the grandeur of a total solar eclipse than from the comfort of an Oceania Cruises ship, where our guests can enjoy this rare cosmic event at sea, away from city lights and distractions,” said Jason Montague, Chief Luxury Officer at Oceania Cruises. “With four ships now positioned within the eclipse path, we are delivering an unparalleled experience combining luxury, enrichment, and an awe-inspiring natural wonder, while maintaining our commitment to delivering The Finest Cuisine at Sea.”

During the eclipse itself, guests will be invited to enjoy a series of vibrant deck parties, offering prime viewing for the main event, alongside celestial festivities and indulgent solar-themed culinary delights designed to celebrate the occasion. Think solar eclipse cookies, star-shaped sandwiches, half-moon shrimp empanadas with chimichurri sauce, eclipse-inspired passion fruit macarons, and more, adding a flavorful touch to the extraordinary experience.




Oceania Marina





 – 14-day Sailing in the Path of 100 Percent Totality

Oceania Marina‘s immersive itinerary sets sail on July 30, 2026, sailing from Copenhagen, Denmark, to Reykjavik, Iceland, with guests invited to visit smaller ports including Invergordon, Scrabster, and Akureyri, and enjoy shore excursions ranging from visits to medieval castles and whale watching to bike tours through unspoiled nature reserves. The prime eclipse viewing will occur while departing port in Grundarfjordur, Iceland. On board, published astronomer, Dennis Mammana, will guide guests through the wonders and mysteries of the cosmos.




Oceania Insignia





 – 12-day Sailing in the Path of 97 Percent Totality

Oceania Insignia‘s captivating sailing, departing August 3, 2026, embarks in Reykjavik, Iceland, and concludes in London (Southampton), United Kingdom. During this sojourn, guests will visit charming boutique ports including Killybegs, Dingle, and Cork, and can experience unique tours, from relaxing in outdoor lagoons or hiking through the Highlands to horseback riding in glacial landscapes. The highlight of the journey will be the prime eclipse viewing, which will take place at sea, near Glengarriff, Ireland. To enrich the experience, astronomer and former NASA space shuttle mission specialist applicant Dr. Jerry Krassner, known as “The Wizard of Stars,” will be on board to share his expertise and guide budding astronomers through the solar eclipse.




Oceania Vista





 – 25-day Sailing in the Path of 93.03 Percent Totality

Oceania Vista‘s captivating 25-day Grand Voyage, sailing round trip London (Southampton), United Kingdom and embarking on August 2, 2026, calls at destinations including Falmouth, Holyhead, and Kristiansand. Shore excursion options include exploring 13th-century medieval castles, walking lush subtropical gardens, and indulging in traditional pub lunches. The solar eclipse will be viewed from a prime position off the coast of Belfast as the ship departs Northern Ireland, heading toward Douglas, Isle of Man (United Kingdom). During the voyage, NASA Solar System Ambassador Ted Blank will captivate guests with his extensive knowledge of astronomy and the solar system.




Oceania Vista





– 15-day Sailing in the Path of 93.03 Percent Totality

For an eclipse cruise of just over two weeks, guests can also join the second segment of Oceania Vista‘s Grand Voyage, which departs from Belfast, Northern Ireland, on August 12, 2026. This 15-day journey to London will take travelers through the British Isles and Baltic gems, including stops in Scrabster, Copenhagen, and Berlin. Guests will have the opportunity to tour renowned whisky distilleries, visit iconic landmarks, and explore cities like a true local, with the highlight being the solar eclipse spectacle.




Oceania Sirena





– 12-day Sailing in the Path of 94 Percent Totality

Departing from London (Southampton), United Kingdom on August 5, 2026, and concluding in Barcelona, Spain, Oceania Sirena’s voyage along the Iberian Peninsula will offer guests the chance to explore picturesque ports such as Ferrol, Oporto, and Almeria. Travelers will have the option to experience one-of-a-kind shore excursions including shepherding for a day, traditional river cruises, and forest cycling adventures. A memorable part of the journey will be the prime eclipse viewing as the ship sails away from Lisbon, Portugal. An enrichment guest speaker is soon to be announced.

For additional information on Oceania Cruises’ small-ship luxury, exquisitely crafted cuisine, and expertly refined travel experiences, visit OceaniaCruises.com, call 855-OCEANIA, or speak with a professional travel advisor.

About Oceania Cruises
Oceania Cruises® is the world’s leading culinary- and destination-focused cruise line. The line’s eight small, luxurious ships carry a maximum of 1,250 guests and feature The Finest Cuisine at Sea® and destination-rich itineraries that span the globe. Expertly curated travel experiences are available aboard the designer-inspired, small ships, which call on more than 600 marquee and boutique ports in more than 100 countries on seven continents, on voyages that range from seven to more than 200 days. Oceania Cruises® has two additional ships on order scheduled for delivery in 2027 and 2028 or 2029[1]. Oceania Cruises® is a wholly owned subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH). To learn more, visit www.nclhltd.com.

[1] Delivery for the second Oceania Cruises ship is contractually scheduled for the fourth quarter of 2028, but may be delayed to 2029.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/oceania-cruises-set-to-take-guests-to-the-stars-and-back-with-five-exceptional-2026-solar-eclipse-sailings-302429491.html

SOURCE Oceania Cruises

Posted on

GUESS JEANS RETURNED TO THE DESERT FOR ITS 4TH ANNUAL BRAND EXPERIENCE–REIMAGINED BY ICONIC JAPANESE GRAPHIC ARTIST VERDY

PR Newswire


LOS ANGELES
, April 16, 2025 /PRNewswire/ — GUESS JEANS made its highly anticipated return to the desert for the fourth year in a row, unveiling a refreshed and reimagined brand experience in collaboration with celebrated Japanese graphic artist and creative force, VERDY. The weekend marked the debut of their new creative partnership, bringing VERDY’s distinct visual language to life across every detail of the multi-day celebration.

Set at an exclusive luxury compound just steps from the Coachella Festival grounds in Indio, California, GUESS JEANS hosted its extended community of artists, tastemakers, and global brand ambassadors during the festival’s opening weekend. Each guest attended the festival and also gained access to a curated lineup of events held on the compound—from an intimate welcome dinner by Jon & Vinny’s to exclusive late-night afterparties.

VERDY infused the weekend with his signature aesthetic—designing all event branding, graphics, and visual identity, including exclusive, unreleased merchandise available only to compound guests. His beloved character Vick made special appearances across the event’s materials, reimagined alongside a playful cartoon version of the GUESS JEANS logo.

“Coachella is the best festival in the world – I was lucky enough to be the Artist in Residence in 2023. I’m excited to return this year with GUESS JEANS to create the ultimate hospitality experience,” says VERDY.

Past compound guests have included the likes of Devon Lee Carlson, J Balvin, Lila Moss, Luka Sabbat and Quenelin Blackwell. This year’s guest list was equally star-studded, including Teyana Taylor, Normani, Lila Moss, Evan Mock, A$AP Nast, Rickey Thompson, Bretman Rock, and Eiza Gonzalez, among others.

Saturday evening, the hottest private party of the weekend took place at the GUESS JEANS compound with an impromptu take over from Charli XCX and her legendary crew of collaborators and friends. Winding down from her momentous performance at Coachella, Charli jumped on the decks for a spontaneous DJ set with her fiancé George Danielfollowing iconic back to back sets from friends Zoe Gitterand Alex Chapman.

Sunday evening rapper, singer-songwriter and long-term collaborator; Don Tolivershuts down Coachella weekend 1 with an a-list private party at the GUESS JEANS desert compound. Coming off his PSYCHO tour, Toliver rolls up to the GUESS JEANS desert compound, bringing DJ sets from Chase B and Anderson Paak. Friends and collaborators, Ty Dolla $ign, Shaboozey, Tyga and YG joined the party and took to the mic for impromptu performances alongside Toliver, keeping the energy of the weekend alive until late.

“Friends and family are at the core of the GUESS JEANS brand. Hosting this annual desert experience gives us the chance to come together, celebrate, and enjoy the community we’ve built over the years. From bringing in people like Don Toliver, who we have an on-going personal & working relationship with, to Charli XCX who we’ve worked with previously, creating bespoke tour looks. It’s important for us to keep those close relationships with the people who support us. California is in our roots and with Indio in our backyard, hosting this annual desert gathering is our way of thanking our extended community for being part of the GUESS JEANS universe,” says Nicolai Marciano, Chief New Business Development Officer, Guess Jeans.

Amongst the star-studded party guestlist: Julia Fox, Alex Consani, Timothee Chalamet, Justin Bieber, Hailey Bieber, Anya Taylor Joy, Cara Delevingne, Paris Hilton, Lorde, Gabriette, Troye Sivan, The Dare, Brooklyn Beckham, Nicola Peltz Beckham, Eiza Gonzalez, Quen Blackwell, Teyanna Taylor, Leonardo DiCaprio, Vittoria Ceretti, Emma Roberts, Tobey Maguire, Tyga, Dixie Demillio, Emma Chamberlain, Alix Earle, Karrueche Tran, Yeat, A$AP Nast, Victoria Monet, Normani, Evan Mock, Clairo, Amelia Dimoldenberg, Lila Moss, Jodie Turner Smith, were all seen arriving for the GUESS JEANS events on Saturday and Sunday.

To round out the weekend’s luxury experience, GUESS JEANS partnered with a number of leading lifestyle brands:

  • GUESS JEANS Eyewear unveiled the first-ever GUESS JEANS sunglasses, exclusively gifted to compound guests ahead of their public release.
  • Dreame Tech provided complimentary blowouts throughout the weekend at an exclusive, invite-only pop-up salon and styling bar hosted by their partner, acclaimed celebrity hairstylist Davontae Washington. VIP guests experienced the innovative Airstyle Pro, featuring JetAirflow™ Technology and Intelligent Heat Control for smooth, optimal, and safe styling.
  • Gin & Juice by Dre and Snoop stocked the bars at both the welcome dinner and afterparties.
  • Recess served as the weekend’s go-to non-alcoholic beverage option.
  • PATRÓN EL ALTO welcomed guests with its exceptionally smooth and naturally sweet handcrafted prestige tequila while also debuting the new PATRÓN EL ALTO mini for everyone to enjoy.
  • Petite Moments offered a personalized charm bar activation for guests to enjoy.
  • Raising Canes provided a branded food truck fuelling guests across both Saturday and Sunday night events.

Each attendee was styled in the latest GUESS JEANS pieces—ranging from timeless denim staples to warm-weather essentials like tanks, tees, and shorts. Guests also debuted custom VERDY x GUESS JEANS merchandise, created exclusively for the occasion and unavailable for public purchase.

Discover the world of GUESS JEANS and shop global collections at GUESSJEANS.com.

GUESS JEANS Desert Compound 2025 Guestlist

Alisha Marie

Alissa Violet

Alyssa Antoci

Andrei Gillott

A$AP Nast

Biel Juste

Bretman Rock

Brian Meller

Carson Tiffany

Carter Gregory

Clara Berry

Coogie

Corrado Martini

Danny Ramirez

Darianka Sanchez

David Dobrik

Denzel Dion

Dru Mac

Evan Mock

FaZe Banks

Fillipo Tenca

Garrett Stevenson

Harry Jowsey

Hayes Bradley

Heath Hussar

Joan Margarit

Jordan Daniels

Jorge Patiño

Juan Pa Gordoa

Justice Fester

Karrueche Tran

Kunichi Nomura

Keiffer Pesca

Lauren Rodgers

Lee Spielman

Lila Moss

Lindsay Margiotti

Luna Blaise

Lydia Asrat

Madeline Argy

Mariah Amato

Matteo Robert

Mariah Amato

Matteo Robert

Mez

Millie Evans

Natalie Noel

Nicolai Marciano

Normani

Olivia Neil

Paulo Calle

Remi Cruz

Reo Sano

Rickey Thompson

Ruby Lyn

Shoji Natsuko

Skyelar Chase

Stella Jones

Teyana Taylor

Tomoko Tanaka

Tori Wade

Tyrell Hampton

Udai

VERDY

Victoria Villarroel

Zane Hijazi

For press enquiries, please contact:
AGENCY ELEVEN
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/guess-jeans-returned-to-the-desert-for-its-4th-annual-brand-experiencereimagined-by-iconic-japanese-graphic-artist-verdy-302430724.html

SOURCE Guess?, Inc.

Posted on

SWKS Investors Have Opportunity to Lead Skyworks Solutions, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, April 16, 2025 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skyworks Solutions, Inc. (NASDAQ: SWKS) between July 30, 2024 and February 5, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline.

So what: If you purchased Skyworks securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Skyworks class action, go to https://rosenlegal.com/submit-form/?case_id=36328 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants provided investors with material information concerning Skyworks’ expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in Skyworks’ ability to expand its mobile business and capitalize on its growth potential by investing in new technologies to diversify its portfolio of offerings. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Skyworks’ client base; notably, that its long-standing relationship with Apple, its largest customer, did not guarantee that Apple would maintain its business relationship with Skyworks for its anticipated iPhone launch. Additionally, defendants oversold Skyworks’ position and ability to capitalize on AI in the smartphone upgrade cycle. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Skyworks class action, go to https://rosenlegal.com/submit-form/?case_id=36328 or https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/swks-investors-have-opportunity-to-lead-skyworks-solutions-inc-securities-fraud-lawsuit-302430584.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

HAOXIN HOLDINGS LIMITED Announces Closing of Initial Public Offering

Ningbo, China, April 16, 2025 (GLOBE NEWSWIRE) — Haoxin Holdings Limited (“Haoxin” or the “Company”) (NasdaqCM: HXHX), a provider of temperature-controlled truckload service and urban delivery services in China, today announced the closing of its initial public offering (the “Offering”) of 1,750,000 Class A ordinary shares at a public offering price of $4 per share. The Class A ordinary shares began trading on Nasdaq Capital Market under the ticker symbol “HXHX” on April 15, 2025.

The Company received aggregate gross proceeds of $7 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters an option, exercisable within 45 days from the date of the underwriting agreement, to purchase up to an additional 262,500 Class A ordinary shares at the public offering price, less underwriting discounts and commissions. The Offering was conducted on a firm commitment basis.

Craft Capital Management LLC and WestPark Capital, Inc. acted as the representatives for the Offering. Ortoli Rosenstadt LLP served as counsel to the Company. Haneberg Hurlbert PLC served as counsel to the underwriters.

A registration statement on Form F-1, as amended (File No. 333-269681) relating to the Offering was previously filed with the Securities and Exchange Commission (“SEC”) by the Company, and subsequently declared effective by the SEC on March 31, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus related to the Offering may be obtained, when available, from Craft Capital Management LLC by emailing [email protected] or calling +1 (800) 550-8411, and from WestPark Capital, Inc. by emailing [email protected] or calling (310) 843-9300.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Haoxin Holdings Limited

Haoxin Holdings Limited is a provider of temperature-controlled truckload service and urban delivery services in China. We mainly provide transportation services with our large and medium-sized temperature-controlled logistics transportation vehicles. We also provide urban delivery services with our medium-sized vans to customers who have short-distance, intra-city delivery needs. The goods we take charge of transporting focus on factory logistics, which include electronic devices, chemicals, fruit, food and commercial goods. Our transportation network covers 30 out of the 34 provinces and autonomous regions in China. For more information, visit the Company’s website at ir.haoxinholdings.com.


Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

For more information, please contact:

Investor Relations:

Sherry Zheng
WAVECREST GROUP INC.
Phone: 718-213-7386
Email: [email protected]



Posted on

ATKR Deadline Alert: ATKR Investors with Losses in Excess of $100K Have Opportunity to Lead Atkore Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, April 16, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atkore Inc. (NYSE: ATKR) between February 1, 2024 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 23, 2025 lead plaintiff deadline.

So what: If you purchased Atkore common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Atkore class action, go to https://rosenlegal.com/submit-form/?case_id=35751 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 23, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Atkore engaged in an anticompetitive price-fixing scheme that artificially inflated the price of PVC Pipes; (2) in turn, Atkore reaped significant, unsustainable financial benefits from its anticompetitive conduct; (3) as Atkore’s price-fixing scheme was exposed, Atkore and its price fixing co-conspirators were no longer able to artificially inflate the price of PVC Pipes, resulting in a substantial decrease in the price of PVC Pipes; (4) Atkore’s business and operations were negatively impacted; and (5) as a result of the above, defendants’ positive statements about Atkore’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Atkore class action, go to https://rosenlegal.com/submit-form/?case_id=35751  or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/atkr-deadline-alert-atkr-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-atkore-inc-securities-fraud-lawsuit-302430557.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

YK Communications and Calix University Grow a Competitive Workforce That Wins on Broadband Experiences

YK Communications and Calix University Grow a Competitive Workforce That Wins on Broadband Experiences

Leveraging a specialized program from Calix University, YK Communications is rapidly transforming their workforce to succeed as a broadband experience provider—shaping future leaders while equipping teams with competitive sales and go-to-market strategies

SAN JOSE, Calif.–(BUSINESS WIRE)–
Today, Calix, Inc. (NYSE: CALX) announced that Texas-based YK Communications is partnering with Calix University to train and build a competitive workforce on their journey to become a broadband experience provider (BXP). Calix University, from the award-winning Calix Success team, is transforming broadband workforces by offering specialized training programs that enhance employee expertise and build new skills. Guided by Calix University’s team, YK increased employee course enrollment by 6X in 90 days—fostering team autonomy, sales and marketing expertise, leadership development, and community outreach.

Calix is committed to developing leadership in the broadband industry. With nearly one-third of the industry’s workforce expected to leave or retire within the next decade, Calix University is innovating its programs to help broadband service providers (BSPs) develop future leaders. Calix University is the only comprehensive broadband education platform that helps BSPs become BXPs. It offers a wide range of educational opportunities, including e-learning, virtual instructor-led courses, and in-person classes. Topics span broadband basics, customer experience, workforce transformation, managed services like Calix SmartLife™, cybersecurity awareness, and more. To meet diverse business needs, Calix University offers flexible education bundles as well as curricula open to all customers. It also partners with community and technical colleges to inspire the next generation of industry leaders.

Their partnership with Calix University is the latest demonstration of how YK embraces the BXP mindset. Recently, Jackie Fowler, director of sales and customer relations at YK, shared her expertise as a featured leader in Calix University, further reinforcing their position in broadband innovation. For over a decade, YK has worked with Calix, transforming their go-to-market strategy to center around exceptional subscriber experiences. Consistently outperforming the telecommunications industry’s average Net Promoter Score℠ (NPS®) in the 30s, YK now boasts an impressive score of 92—driven by early adoption of value-based offers like the “Family Guardian” plan. This offer includes managed services like ExperienceIQ® advanced network controls, ProtectIQ® cybersecurity, Bark social media monitoring, and Arlo Secure connected property cameras.

“With ongoing commoditization in our industry and an aging workforce, every broadband business is at a crossroads,” said Russell Kacer, president at YK Communications. “For any general manager, the key differentiator is your team and experiences. To quickly adapt, we teamed up with Calix to transform our workforce. Working side-by-side with the Calix team to develop a specialized playbook, our employees love how Calix University streamlines learning—earning an outstanding 4.92 out of 5 satisfaction score. To keep us ahead of the curve, we continue to invest in our future with Calix innovation, ensuring our South Texas communities receive even greater value that transcends speed and price.”

“At Calix, we see customer experience as an ongoing journey—not a destination,” said John Durocher, chief customer officer at Calix. “Russell is a great example of someone who embraces that mindset. As YK Communications continues to transform their business and focus on experiences rather than price or speed, they know their teams will need to develop new skills and strategies to succeed. We have been thrilled with the results of their collaboration with Calix University. We will continue to innovate Success programs and help our customers develop the next generation of leaders for the broadband industry.”

Explore Calix University, a learning platform dedicated to advancing the future broadband workforce.

About Calix

Calix, Inc. (NYSE: CALX)—Calix is a platform, cloud, and managed services company. Broadband service providers leverage Calix’s broadband platform, cloud, and managed services to simplify their operations, subscriber engagement, and services; innovate for their consumer, business, and municipal subscribers; and grow their value for members, investors, and the communities they serve.

Our end-to-end platform and managed services democratize the use of data—enabling our customers of any size to operate efficiently, acquire subscribers, and deliver exceptional experiences. Calix is dedicated to driving continuous improvement in partnership with our growing ecosystem to support the transformation of our customers and their communities.

This press release contains forward-looking statements that are based upon management’s current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this release, and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release, except as required by law. Actual results and the timing of events could differ materially from current expectations based on risks and uncertainties affecting Calix’s business. The reader is cautioned not to rely on the forward-looking statements contained in this press release. Additional information on potential factors that could affect Calix’s results and other risks and uncertainties are detailed in its quarterly reports on Form 10-Q and Annual Report on Form 10-K filed with the SEC and available at www.sec.gov.

Calix and the Calix logo are trademarks or registered trademarks of Calix and/or its affiliates in the U.S. and other countries. A listing of Calix’s trademarks can be found at https://www.calix.com/legal/trademarks.html. Third-party trademarks mentioned are the property of their respective owners.

Net Promoter®, NPS®, NPS Prism®, and the NPS-related emoticons are registered trademarks of Bain & Company, Inc., Satmetrix Systems, Inc., and Fred Reichheld. Net Promoter Score℠ and Net Promoter System℠ are service marks of Bain & Company, Inc., Satmetrix Systems, Inc., and Fred Reichheld.

Press Inquiries:

Zach Burger

669-369-1991

[email protected]

Investor Inquiries:

Nancy Fazioli

[email protected]

KEYWORDS: United States North America California Texas

INDUSTRY KEYWORDS: Telecommunications Networks Internet Other Education Technology Education Mobile/Wireless Training

MEDIA:

Logo
Logo
Posted on

VG Deadline: VG Investors with Losses in Excess of $100K Have Opportunity to Lead Venture Global, Inc. Securities Lawsuit

PR Newswire


NEW YORK
, April 16, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Venture Global, Inc. (NYSE: VG) pursuant and/or traceable to Venture Global’s registration statement for the initial public offering conducted on or about January 24, 2025 (the “IPO”), of the important April 18, 2025 lead plaintiff deadline.

So what: If you purchased Venture Global stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Venture Global class action, go to https://rosenlegal.com/submit-form/?case_id=35218 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants touted its innovative and disruptive approach, which they stated is both scalable and repeatable, allowing Venture Global to bring liquified natural gas (“LNG”) to the global market years faster and at a lower cost. Defendants further discussed the development of Venture Global’s five natural gas liquefaction and export projects near the Gulf of Mexico in Louisiana, utilizing their unique “design one, build many” approach. Therefore, the IPO represented to the public that Venture Global had the customer backing to implement its projects, allowing for Venture Global to deliver LNG to the world. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Venture Global class action, go to https://rosenlegal.com/submit-form/?case_id=35218 call Phillip Kim, Esq. toll-free at 866-767-3653, or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vg-deadline-vg-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-venture-global-inc-securities-lawsuit-302430530.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

  • Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
  • Pericarditis is an inflammation of the pericardium, the sac-like membrane that surrounds and protects the heart. It occurs when the pericardium becomes irritated or infected, leading to swelling and pain.

PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that FDA has approved our request for the Orphan drug designation for colchicine for the treatment of pericarditis.

Gloperba® is taken orally like cough syrup. The dosage of 0.6mg per 5ml (teaspoon) can fill that important void in treatment where patients may have difficulty swallowing pills. It can also provide more adjustable dosing, titration and dose-reduction options in specific populations, especially for gout patients with renal or hepatic impairment and reduce side effects with the goal to improve patient convenience and disease management.

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

[email protected]

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex Holding Company is headquartered in Palo Alto, California.

About Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly-owned subsidiary of Scilex, is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.

Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the granting of Orphan drug designation status by the FDA, the estimates for the obesity drug treatment and Alzheimer’s global drug market and the global spending figures, KDS2010’s potential to demonstrate a more favorable efficacy profile compared to existing obesity treatments, Scilex Bio JV’s ability to develop and commercialize treatments for obesity, neurodegenerative, and cardiometabolic disease.

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex’s ability to gain market acceptance of KDS2010; Scilex’s ability to develop and commercialize treatments for obesity, neurodegenerative, or cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: [email protected]

Website: www.scilexholding.com

References

  1. Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008
  2. Stewart et al. Arthritis Research & Therapy (2020) 22:28; https://doi.org/10.1186/s13075-020-2120-7
  3. https://www.sciencedirect.com/science/article/pii/S0049017220301220
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC10285625/

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.



Posted on

Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Five Below insiders caused the company to misrepresent or fail to disclose the true nature of the company’s financial strength and operations, including its outlook for the first quarter and full year 2024. On June 5, 2024, FIVE announced disappointing first quarter 2024 sales result and cut its full year 2024 guidance stating, “Net sales are expected to be in the range of $3.79 billion to $3.87 billion based on opening approximately 230 new stores.” At the same time, FIVE claimed that for the second quarter, “Net sales are expected to be in the range of $830 million to $850 million based on opening approximately 60 new stores.”

If you currently own FIVE and purchased prior to December 1, 2022 please contact Justin Kuehn, Esq. here, by email at [email protected] or call (833) 672-0814.  The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO’s commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO’s prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO’s prescription data; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you currently own Amylyxand purchased prior to November 11, 2022 please contact Justin Kuehn, Esq. here, by email at [email protected], or call (833) 672-0814.  The consultation and case are free with no obligation to you. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814